RxDoctor Payments Data

Paolo Romanelli, MD

Dermatology · Miami, FLNPI 1013945724

Payments from drug & device makers

$53,832in general payments, 2019–2025

Across 241 payments — averaging $223.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Boehringer Ingelheim International GmbH$10K
  • UCB, Inc.$6K
  • Novartis$4K
  • Sun Pharmaceutical Industries Inc.$3K
  • Boehringer Ingelheim$3K
  • plus $10K from 16 others

What the payments were for

  • Consulting fees$26,13066%
  • Speaking & faculty fees$1,8235%
  • Travel & lodging$350%
  • Food & beverage$11,80830%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,832 in reported general payments places this provider in the 85th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$39,642
Medicare patients
136
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$335,373
Cosentyx Sensoready (2 Pens)Secukinumab39$277,358
TremfyaGuselkumab18$239,306
Bimzelx AutoinjectorBimekizumab-Bkzx15$217,134
Cosentyx (2 Syringes)Secukinumab13$98,836
Dupixent PenDupilumab25$93,534
Dupixent SyringeDupilumab26$91,325
OpzeluraRuxolitinib Phosphate28$59,419
ZoryveRoflumilast12$11,336
Tacrolimus22$2,091
Clobetasol Propionate47$1,762
Calcipotriene12$1,688
Triamcinolone Acetonide58$1,126
Fluocinolone Acetonide16$790
MethotrexateMethotrexate Sodium25$462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,806$239,30618 claims
NovartisCosentyx (2 Syringes)$4,258$98,83613 claims
Incyte CorporationOpzelura$278$59,41928 claims
Arcutis Biotherapeutics, Inc.Zoryve$190$11,33612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →